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Abstract
Background: This study was designed to investigate the effects of the vitamins C and B12 on the regulation of
human nasal ciliary beat frequency (CBF).
Methods: Human nasal mucosa was removed endoscopically and nasal ciliated cell culture was established. Changes of
CBF in response to different concentrations of vitamin C or vitamin B12 were quantified by using high-speed (240 frames
per second) digital microscopy combined with a beat-by-beat CBF analysis.
Results: At the concentrations of 0.01% and 0.10%, vitamin C induced an initial increase, followed by a gradual decrease
of CBF to the baseline level, while 1.00% vitamin C induced a reversible decrease of CBF. Vitamin B12, at the
concentrations of 0.01% and 0.10%, did not influence CBF during the 20-min observation period, while a 1.00% vitamin
B12 treatment caused a time-dependent but reversible decrease of CBF.
Conclusions: Treatment with vitamin C or vitamin B12 caused a concentration-dependent but reversible decrease of CBF
in cultured human nasal epithelial cells. Therefore, it is necessary to choose a concentration that is safe, effective, and
non-ciliotoxic when applying these drugs topically in the nasal cavity.
Keywords: Ciliary beat frequency, Vitamin C, Vitamin B12, Nasal epithelial cell
Background
Intranasal administration as a non-invasive route for drug
delivery has generated much interest within the pharma-
ceutical industry in recent years. The nasal mucosa has
many advantages as a potential site for both topical and
systemic drug delivery, which include a large surface area
for delivery, rapid onset of therapeutic effect, potential for
central nervous system delivery, no first-pass metabolism,
and, owing to its non-invasive nature, is likely to maximize
patient comfort and compliance [1].
The safety of drug administration is an important param-
eter that must be taken into consideration during intranasal
drug delivery. The nasal mucosa is lined by pseudostratified
columnar ciliated epithelium. Coordinated beating of epi-
thelial cell cilia with a normal pattern and frequency, which
induces clearance of mucus from the airway, is the driving
force of respiratory mucociliary transport. Impairment of
the nasal mucociliary transport system can produce serious
consequences because mucociliary transport is a major
defense mechanism of the respiratory tract [2]. Therefore,
investigation of the influence of nasally-administered drugs
on ciliary activity is of great importance to assessing drug
safety.
Vitamin C (ascorbic acid) is an important antioxidant in
the respiratory tract, it is also an effective anti-inflammatory
and anti-allergic agent; supplementation of vitamin C has
been verified as an effective therapy for the treatment of
certain respiratory diseases, including allergic rhinitis [3],
chronic rhinosinusitis [4], and the common cold [5]. Since
intranasal delivery route is commonly used for rhinologic
drugs, we consider the intranasal route as a possible route
for vitamin C supplementation, either alone or as an ingre-
dient of certain drugs or medications.
Vitamin B12 (cobalamin) is necessary for the develop-
ment of red blood cells, growth, and proper functioning
of the nervous system [6]. Vitamin B12 deficiency is
frequently found in elderly patients, with the main
causes being pernicious anemia and food-cobalamin
malabsorption. Management of vitamin B12 deficiency
with cobalamin injections is currently well documented,
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but new routes for the administration of vitamin B12,
both nasal and oral, are currently being developed [7].
The aim of the present study was to assess the ciliary
toxicity of a range of concentrations of vitamin C or
vitamin B12 treatment on cultured human nasal epithe-
lial cells, so as to provide some advice for drug develop-
ment and clinical medication.
Methods
Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM), Dulbecco’s
Modified Eagle’s Medium/Ham’s F12 (DMEM/F12), Hank’s
balanced salt solution (HBSS) and antibiotics were
purchased from GIBCO BRL (Grand Island, NY, USA).
Vitamin C was provided by Prof. Zinreich (Johns Hopkins
Hospital, Baltimore, USA). Vitamin B12, human placental
collagen, protease, and all other chemicals were obtained
from Sigma-Aldrich (St. Louis, MO, USA).
Human nasal epithelial cell cultures
This study was performed at the Department of Otolaryn-
gology, Head and Neck Surgery, Beijing TongRen Hospital.
The study protocol was reviewed and approved by the local
ethics board of Beijing TongRen Hospital, Capital Medical
University. Informed consent was obtained from all the
participants.
Human uncinate process was endoscopically obtained
from 8 adult patients who had cerebrospinal fluid rhinorrhea,
nasopharyngeal angiofibroma or nasal septum deviation,
without acute rhinosinusitis, chronic rhinosinusitis or
allergic rhinitis.
Primary culture of human nasal epithelial cells was
established using an adaptation of the methods pub-
lished by Nlend et al. [8]. The dissected mucosa was in-
cubated in 0.05% protease (type XIV) in DMEM
overnight at 4°C. After protease treatment, epithelial
cells were released by vigorous shaking and were
harvested by centrifugation. The cells were plated on
collagen-coated glass coverslips (human placental colla-
gen, type IV) at a density of 5×105/ml. The medium
consisted of DMEM/F12 supplemented with 10 μg/ml
insulin, 5 μg/ml transferrin, 0.36 μg/ml hydrocortisone,
20 ng/ml triiodothyronine, 7.5 μg/ml endochelial cell
growth supplement, 100 U/ml penicillin and 100 μg/ml
streptomycin. Cells were grown in an incubator at 37°C
in 5% CO2. The medium was changed every other day.
Measurements of ciliary beat frequency
Ciliary beat frequency was measured on the 1st, 3rd, 7th
and 14th day of cell culture. Cell cultures between the
3rd to 14th days were used for CBF measurements in
response to 3 different concentrations of vitamin C or
vitamin B12 (0.01%, 0.10%, 1.00%), as well as HBSS.
HBSS was used as a negative control to rule out the
influence of the turbulence caused by changing the solu-
tion in the cell chamber.
The cultures were first allowed to equilibrate to 25°C for
10 minutes, and initially measured for three seconds to
obtain a baseline CBF by rinsing with Locke Ringer’s solu-
tion (136 mM NaCl, 5.6 mM KCl, 10 mM HEPES,
14.3 mM NaHCO3, 1.2 mM MgCl2, 2.2 mM CaCl2 and
11.5 mM dextrose, pH 7.35). The cultures were then
treated with the appropriate concentration of vitamin C,
vitamin B12, or HBSS, and CBF was continuously
recorded for three seconds every 1 minute for 20 minutes.
For high concentration of vitamins, namely, 1.00%
vitamin C or 1.00% vitamin B12, after CBF measure-
ments in vitamins solution for 20-min time-period, the
cultures were followed by wash-out with the Locke
Ringer’s solution for another 20 minutes.
Measurements of CBF were made according to a pre-
viously published method [9,10]. Briefly, ciliated epithe-
lial cells were viewed with an Olympus IX71 inverted
microscope (Tokyo, Japan) equipped with a ×40, 1.3 NA,
Ph 4, oil immersion objective. Imaging of cilia move-
ment was carried out at 25°C and was achieved by
directing the light forming the phase-contrast images
to a high-speed CCD camera (TM-6710CL, Pulnix
America, Sunnyvale, CA, USA). The camera was
coupled with a frame grabber (Meteor, Matrox Electronic
Systems, Dorval, Quebec, Canada) and recording software
(StreamPix 3.16.5, Norpix Inc, Montreal, Quebec, Canada).
The phase-contrast images of cilia movement were recorded
at 240 frames per second. Images were evaluated using an
image analysis program (IPLab v3.65a, Scanalytics, Inc.,
Fairfax, VA, USA).
The frequency of each ciliary beat cycle was calculated
from the period of each cycle of the gray intensity wave-
form by a beat-by-beat analysis. The data analysis ap-
proach can measure the period [frequency (hertz) =
1/period] of each ciliary beat cycle to match the high
temporal resolution of the image capture rate. The CBF
was measured using a 3-second waveform (~720 frames)
that was generated by the variation in gray level intensity
of the phase-contrast images that resulted from the re-
petitive motion of the cilia. A region of interest, near
the ciliary tip when the cilia were lying in the rest
phase position, was selected and the average gray value
was digitally extracted from the image data set and
plotted with respect to time (i.e. frame number). The
frequency of each ciliary beat cycle was determined
from the period of each cycle of the gray intensity
waveform.
Statistics
The data were expressed as means ± SEM. Statistical
significance was assessed using a Repeated Measures
ANOVA followed by Bonferroni’s multiple comparison
Jiao et al. BMC Complementary and Alternative Medicine 2013, 13:110 Page 2 of 6
http://www.biomedcentral.com/1472-6882/13/110
test. A value of p < 0.05 was considered statistically
significant.
Results
Ciliary beat frequency on different culture day
On the 1st, 3rd, 7th, and 14th day of cell culture, CBFs
of cultured cells were 7.32±1.55 Hz, 10.75±1.53 Hz,
10.73±2.15 Hz and 9.92±1.97 Hz, respectively. The CBF
on the 1st day is significantly lower than the other days;
in addition, the CBFs from the 3rd to 14th day are most
close to the CBF of in vivo nasal epithelial cells, which is
from 9 to 15 Hz. Therefore, we choose cell cultures from
the 3rd to 14th day for CBF measurements in the
following experiments.
Changes of CBF in response to vitamin C
The baseline CBF (CBF before treatment) for each of the
three vitamin C groups and the HBSS group was 9.15 ±
1.07 Hz, 8.82 ± 1.29 Hz, 10.03 ± 1.67 Hz and 8.78 ±
1.56 Hz, respectively. There was no significant difference
in baseline CBF within the groups (Figure 1).
Following treatment with 0.01% vitamin C, human
nasal CBF increased over the first 2 min. The highest
CBF, which was 10.13 ± 1.56 Hz, was observed at the
first measurement point (1 min). CBF then gradually de-
creased to the baseline level. No distinguishable change
in CBF relative to the baseline CBF was identified over
the subsequent 18 min (Figure 1).
Similarly, 0.10% vitamin C increased CBF over the first
4 min. The highest CBF, 10.07 ± 1.77 Hz, was again
observed at 1 min after treatment. CBF then gradually
decreased to the baseline level. No distinguishable
change in CBF relative to the baseline CBF was identi-
fied over the subsequent 16 min (Figure 1).
Ciliary beat frequency decreased significantly in response
to the addition of 1.00% vitamin C. Initially, the CBF
remained constant for approximately 10 min, and then
continued to decrease over the next 10 min. At 20-min
time-point after drug treatment, the CBF decreased to
6.84 ± 1.09 Hz (Figure 1). However, after wash-out with
Locke Ringer’s solution, the CBF recovered rapidly in a
time-dependent manner; CBF on 5-min time point during
wash-out period recovered to 108.16 ± 3.32% of baseline
CBF (Figure 2).
On treatment with HBSS, no discernible change in
CBF relative to the baseline CBF was identified during
the 20 minute measurement period (Figure 1).
Changes of CBF in response to vitamin B12
Ciliary beat frequency changes in response to vitamin B12
are shown in Figures 3 and 2. Baseline CBF for the 0.01%,
0.10%, 1.00% vitamin B12 and HBSS groups was 8.96 ±
1.02 Hz, 9.35 ± 2.55 Hz, 10.23 ± 2.30 Hz and 9.07 ±
1.67 Hz respectively. No significant difference was found
in baseline CBF within the groups (Figure 3).
Treatment with 0.01% and 0.10% vitamin B12 induced
no significant change in CBF during the entire 20-minute
measurement period. The CBF ranged from 8.96 ±
1.02 Hz and 9.35 ± 2.55 Hz (before treatment) to 9.46 ±
0.26 Hz and 8.95 ± 0.72 Hz (20 min after treatment) re-
spectively (Figure 3).
At a concentration of 1.00%, vitamin B12 induced a
gradual decrease in CBF and statistical significance was
identified at the last three 1-minute time points. At
20 min after 1.00% vitamin B12 treatment, CBF had
Figure 1 Changes of CBF in response to vitamin C. Ciliary beat
frequency of cultured human nasal epithelial cells, measured before
and every 1 min after treatment with 0.01% (n = 7, green dotted
line), 0.10% (n = 7, blue dotted line) and 1.00% (n = 7, red dotted
line) vitamin C, or HBSS (n = 7, black dotted line) over 20 minutes.
*P < 0.05, vs. 0 min of each group.
Figure 2 Changes of CBF in response to vitamins wash-out.
Ciliary beat frequency of cultured human nasal epithelial cells,
measured before and after treatment with 1.00% vitamin C (n = 5),
or 1.00% vitamin B12 (n = 5) over 20 minutes, followed by another
20 minutes wash-out with Locke Ringer’s solution. *P < 0.05, vs. 20-
min time-point of vitamin C treatment, #P < 0.05, vs. 20-min time-
point of vitamin B12 treatment.
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decreased from 10.23 ± 2.30 Hz (baseline CBF) to 7.78 ±
2.34 Hz (Figure 3).
At concentration of 1.00%, vitamin B12-induced CBF
depression was also reversible, since the CBF was
restored to the baseline level even after 1 minute of rins-
ing with Locke Ringer’s solution, CBF at 1-min wash-out
period reached to 97.68 ± 14.08% of baseline CBF
(Figure 2).
Following treatment with HBSS, no discernible change
in CBF relative to baseline CBF was identified during the
20 minute measurement period (Figure 3).
Discussion
Vitamin C is a well-known water-soluble and potent
antioxidant, which exerts its antioxidant effect through
scavenging reactive oxygen species by very rapid aque-
ous phase electron transfer, and preventing initiation of
lipid peroxidation [11]. Vitamin C also has anti-
inflammatory and anti-allergic effects; it might modulate
the immune system by affecting the functions of phago-
cytes, proliferation of T lymphocytes, production of
interferon, and gene expression of monocyte adhesion
molecules [12]. In addition, vitamin C has been reported
to be a biological regulator of the cystic fibrosis trans-
membrane conductance regulator (CFTR), which is a
cAMP-dependent chloride channel that regulates re-
spiratory tract epithelial surface fluid secretion, as well
as controlling the hydration of mucosal surfaces and
promoting effective mucociliary clearance. Topical ad-
ministration of vitamin C to freshly-excised sinus and
nasal mucosa was found to enhance chloride secretion,
suggesting a potential for use as a therapeutic agent for
the improvement of mucociliary clearance [13,14].
Given that oxidative damage, inflammation, immuno-
logical disturbance, and impairment of mucociliary
clearance are common pathogenic factors associated
with the pathogenesis of various rhinological diseases,
such as chronic rhinosinusitis and allergic rhinitis, sup-
plementation with vitamin C could have great potential
as a novel therapy, either alone or in combination with
traditional medications for the treatment of these dis-
eases. In fact, some basic and clinical research has
reported the effectiveness of vitamin C supplementation
for the treatment of some respiratory diseases [3,4,15].
However, at present, most vitamin C delivery is by oral
supplementation. Since most traditional medications for
nasal disease, such as corticosteroid, antihistamines and
vasoconstrictors, can be applied intranasally, we consider
the intranasal delivery route as a possible route for vita-
min C administration.
Vitamin B12 deficiency is common in the elderly
(> 65 years of age), but is often unrecognized because of
its subtle clinical manifestations, although they can be po-
tentially serious, particularly from a neuropsychiatric and
hematological perspective [16]. The main causes of vita-
min B12 deficiency include pernicious anemia and food-
cobalamin malabsorption, as well as poor diet, age-related
gastric mucosal changes, and polypharmacy. Management
of vitamin B12 deficiency with cobalamin injections is
currently well-codified, but new routes of cobalamin ad-
ministration (oral and nasal) are being studied, and several
studies have confirmed the effectiveness of oral or nasal
vitamin B12 supplementation serving as an alternative for
intramuscular injection [17,18]. Compared with oral ther-
apy, intranasal vitamin B12 supplementation could
improve systemic absorption and ease of administration,
avoid drug complexation with intrinsic factor in the
process of oral absorption [18], and have a minimal poten-
tial for adverse systemic effects. However, although the
intranasal route for vitamin B12 delivery has increasingly
been used in clinical practice, the drug safety of topical
form in vitamin B12 has been ignored.
Based on the common view that an effect on
mucociliary clearance is one of the major areas of tox-
icity for nasal drug administration, the present study was
designed to assess the ciliary toxicity of these two vita-
mins for intranasal application. CBF is a basic parameter
for evaluation of ciliary activity, therefore, measurements
of CBF changes in response to exogenous drugs on
in vitro nasal epithelial cell cultures are commonly used
to assess drug safety. However, the in vitro nasal epithe-
lial cell culture do not represent in vivo nasal mucosa, it
is reported that CBF of in vitro cultured cells may
change over the culture time, moreover, the CBF be-
tween in vivo human nasal epithelial cells and cultured
human nasal epithelial cells is different over the culture
time [19]. Therefore, we first measured the CBF of
Figure 3 Changes of CBF in response to vitamin B12. Ciliary
beat frequency of cultured human nasal epithelial cells, measured
before and every 1 min after treatment with 0.01% (n = 8, green
dotted line), 0.10% (n = 8, blue dotted line) and 1.00% (n = 8, red
dotted line) vitamin B12, or HBSS (n = 8, black dotted line) over
20 minutes. *P < 0.05, vs. 0 min of each group.
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cultured cells on different culture-time. Our results
showed that CBF from the 3rd to 14th day is most close
to the CBF of in vivo nasal epithelial cells, so we choose
cell cultures from 3rd to 14th days for measurements of
CBF in response to exogenous drugs.
We found that within concentrations from 0.01% to
0.10%, vitamin C had a stimulatory effect on human
nasal CBF. However, at a higher concentration (1.00%),
vitamin C produced an inhibitory but reversible effect
on CBF. The effects of vitamin B12 on CBF were similar
with that of vitamin C. At lower concentrations (from
0.01% to 0.10%), vitamin B12 has no significant effect on
human nasal CBF. However, a higher concentration of
vitamin B12, 1.00%, induced a time-dependent but also
reversible decrease of human nasal CBF. These results
raise the possibility of inducing loss of ciliary activity
with higher concentrations of vitamins when applied
intranasally, indicating the necessity of choosing a safe,
non-ciliotoxic concentration when applying the vitamins
topically in the nasal cavity.
The mechanisms of changes in CBF in response to vita-
mins treatment are still unclear. Airway CBF is mainly regu-
lated by a variety of intracellular second messenger signaling
mechanisms including cyclic adenosine monophosphate
(cAMP), cyclic guanosine monophosphate (cGMP), and
calcium [20]. cAMP activates an axonemal protein kinase A
(PKA) to phosphorylation a dynein light chain to increase
CBF; cGMP mediates a phosphorylation or dephosphoryla-
tion event to increase CBF via protein kinase G (PKG) and
possibly PKA; calcium seems to increase CBF via an initial
direct action on the axoneme and subsequently via cross
talk to the cAMP or cGMP pathways. A significant amount
of work is required to understand fully the mechanisms of
regulation of CBF by these vitamins.
There are several other limitations of the current study.
First, due to the short life-span of in vitro cultured epithe-
lial cells, the effects of two vitamins on CBF were observed
for only short period of 20 minutes; however, the use of
vitamin C or B12 is not the single use but long term use
in clinical medication, in addition, the present study
showed a reversible decrease of CBF caused by single use
of vitamins at high concentration, further indicating a pos-
sible long term ciliary toxicity in clinical use. Therefore, in
the following studies, we are going to further assess the
long term drug safety in vivo on laboratory animal models.
Second, our experiments were performed on relatively
normal nasal mucosa of patients, but not patients with
acute or chronic rhinosinusitis. Since mucociliary
transport and CBF make a difference in normal and
inflammatory conditions, additional experiments for
these inflammatory patients will provide more convin-
cing results. In fact, we are in the process of performing
further study on these patients so as to provide more
detailed information for drug safety.
Conclusions
In summary, to the best of our knowledge, this study is
the first to assess the influence of vitamin C and vitamin
B12 on CBF in primary cultured human nasal epithelial
cells. We have found that vitamin C, within a range of
concentrations from 0.01% to 0.10%, has a stimulatory
effect on human nasal CBF, while at a higher concentra-
tion (1.00%), it produces an inhibitory but reversible
effect on CBF. Low concentrations (from 0.01% to
0.10%) of vitamin B12 have no obvious effect on CBF,
while at a higher concentration (1.00%), it also induced a
time-dependent but reversible decrease in human nasal
CBF. These results do suggest the need for choosing a
concentration that is effective, safe and non-ciliotoxic
when applying these agents topically in the nasal cavity.
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